Pipeline
Pipeline

Jazz’s development pipeline includes the clinical development of new therapies to treat unmet medical needs, line extensions for existing products, and the generation of additional clinical data for existing products.

R&D Pipeline

Pipeline

Updated 02/28/2017

1 NDA submissions assume positive study outcomes.
2 Evaluation of deuterated oxybate continues as part of the once-nightly development process; JZP-386 formulation work ongoing.
3 Evaluating early stage product candidates, including recombinant pegaspargase.
AML = Acute Myeloid Leukemia, NDA = New Drug Application, MAA = Marketing Authorization Application, ES = Excessive Sleepiness, OSA = Obstructive Sleep Apnea, EDS = Excessive Daytime Sleepiness, sNDA = Supplemental New Drug Application, VOD = Hepatic Veno-occlusive Disease, FPI = First Patient In, GvHD = Graft versus Host Disease, ALL = Acute Lymphoblastic Leukemia